Robert J. de Knegt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert J. de Knegt has a total of 468 co-authors. Here are the top co-authors by number of shared publications:
- Laurens A. van Kleef
Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
25 shared publications - Milan J. Sonneveld
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
14 shared publications - Bettina E. Hansen
Department of Epidemiology, Erasmus MC—Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
12 shared publications - Harry L. A. Janssen
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
11 shared publications - Willem Pieter Brouwer
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
11 shared publications Harry L.A. Janssen
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands
10 shared publications
Latest Publications
- Open Access
CD8 T cells with classical and NK-like cytotoxic gene expression programs mediate control of HBV replication and functional cure
Summary: Chronic hepatitis B is characterized by a decades-long evolving engagement between host immunity and the hepatitis B virus (HBV). Understanding the molecular characteristics of HBV-specific CD8 T cells linked to control of viral replication and antigenemia is essential to design effective immunotherapeutic modalities. Here we show that HBV-specific CD8 T cells, even during infection stages with extremely high viral loads, lack the features of terminally exhausted CD8 T cells observed in chronic HCV and HIV infection or cancer. Instead, we observe emerging gene expression programs over disease stages that correlate with increasing HBV control, which include a bona fide cytotoxic and T-cell localization program associated with low levels of viral replication, and a second NK-like T-cell program that combines expression of classical NK markers ( KIR s, KLR s, FCGR3A , TYROBP , IKZF2 ) with cytotoxic genes ( GZMB , GNLY , PRF1 ), which emerges with complete control of HBV viremia and antigenemia. We also found enrichment of both CD8 T-cell programs in HIV-specific CD8 T cells from HIV elite controllers, supporting a conserved role in controlling persistent viral infections with viral reservoirs.
Open AccessCD8 T cells with classical and NK-like cytotoxic gene expression programs mediate control of HBV replication and functional cure
Summary: Chronic hepatitis B is characterized by a decades-long evolving engagement between host immunity and the hepatitis B virus (HBV). Understanding the molecular characteristics of HBV-specific CD8 T cells linked to control of viral replication and antigenemia is essential to design effective immunotherapeutic modalities. Here we show that HBV-specific CD8 T cells, even during infection stages with extremely high viral loads, lack the features of terminally exhausted CD8 T cells observed in chronic HCV and HIV infection or cancer. Instead, we observe emerging gene expression programs over disease stages that correlate with increasing HBV control, which include a bona fide cytotoxic and T-cell localization program associated with low levels of viral replication, and a second NK-like T-cell program that combines expression of classical NK markers ( KIR s, KLR s, FCGR3A , TYROBP , IKZF2 ) with cytotoxic genes ( GZMB , GNLY , PRF1 ), which emerges with complete control of HBV viremia and antigenemia. We also found enrichment of both CD8 T-cell programs in HIV-specific CD8 T cells from HIV elite controllers, supporting a conserved role in controlling persistent viral infections with viral reservoirs.
- Open Access
- 18 April 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (7) , 101865
Persistent loss of intrahepatic IFN-γ in HBV is linked to selective impairment of liver-resident CXCR6+NK cells despite long-term NUC therapy
- 18 April 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (7) , 101865
Open AccessPersistent loss of intrahepatic IFN-γ in HBV is linked to selective impairment of liver-resident CXCR6+NK cells despite long-term NUC therapy
- Open Access
- 28 November 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 967-978
Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt
Objectives: Transjugular intrahepatic portosystemic shunt (TIPS) placement effectively decreases portal pressure in patients with decompensated cirrhosis. However, many patients develop hepatic encephalopathy (HE) post‐TIPS. We investigated the relation between the presence of Diabetes Mellitus (DM) and the occurrence of HE following TIPS placement in patients with cirrhosis. Methods: In this retrospective cohort study all patients with cirrhosis who received a TIPS from 2007 through 2021 were included. Baseline characteristics and decompensating events including hospital admission for HE were recorded. In cases where hospital admission was required, HE was considered severe. Results: In total, 325 patients were included and 113 (34.8%) had DM at the time of TIPS placement. One hundred and fifty‐one patients developed HE of whom 86 (57.0%) were hospitalised. The cumulative 6‐month incidences of HE and severe HE were 45.2% (95% CI 39.5–51.8) and 25.1% (95% CI 20.2–31.3), respectively. Multivariable Cox regression with competing risk analyses demonstrated that DM was independently associated with the risk of both HE (aHR 1.56, 95% CI 1.08–2.26, p = 0.018) and severe HE (aHR 1.76, 95% CI 1.07–2.90, p = 0.026). These associations were independent of the relation between HE and age (aHR 1.03, 95% CI 1.01–1.05, p < 0.001) or MELD‐Na score (aHR 1.07, 95% CI 1.03–1.10, p < 0.001). Conclusions: This study highlights the high incidence of HE following TIPS and shows that DM is a significant and independent risk factor for the development of HE. Given the increase in patients with metabolic dysfunction‐associated liver cirrhosis and DM, this study offers additional insights into the balance of risks and benefits associated with TIPS placement.
- 28 November 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 967-978
Open AccessDiabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt
Objectives: Transjugular intrahepatic portosystemic shunt (TIPS) placement effectively decreases portal pressure in patients with decompensated cirrhosis. However, many patients develop hepatic encephalopathy (HE) post‐TIPS. We investigated the relation between the presence of Diabetes Mellitus (DM) and the occurrence of HE following TIPS placement in patients with cirrhosis. Methods: In this retrospective cohort study all patients with cirrhosis who received a TIPS from 2007 through 2021 were included. Baseline characteristics and decompensating events including hospital admission for HE were recorded. In cases where hospital admission was required, HE was considered severe. Results: In total, 325 patients were included and 113 (34.8%) had DM at the time of TIPS placement. One hundred and fifty‐one patients developed HE of whom 86 (57.0%) were hospitalised. The cumulative 6‐month incidences of HE and severe HE were 45.2% (95% CI 39.5–51.8) and 25.1% (95% CI 20.2–31.3), respectively. Multivariable Cox regression with competing risk analyses demonstrated that DM was independently associated with the risk of both HE (aHR 1.56, 95% CI 1.08–2.26, p = 0.018) and severe HE (aHR 1.76, 95% CI 1.07–2.90, p = 0.026). These associations were independent of the relation between HE and age (aHR 1.03, 95% CI 1.01–1.05, p < 0.001) or MELD‐Na score (aHR 1.07, 95% CI 1.03–1.10, p < 0.001). Conclusions: This study highlights the high incidence of HE following TIPS and shows that DM is a significant and independent risk factor for the development of HE. Given the increase in patients with metabolic dysfunction‐associated liver cirrhosis and DM, this study offers additional insights into the balance of risks and benefits associated with TIPS placement.
- 7 May 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 591-602
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction
Background and Aims: Screening for liver disease in the general population requires accurate non-invasive tests (NITs). A head-to-head comparison of NITs for early detection of clinically relevant liver disease among the target population for screening is lacking. Aproach and Results: Among the meta-cohort (Rotterdam Study and National Health and Nutrition Examination Survey) with metabolic dysfunction aged 18–80 years, 10 NITs were investigated. The diagnostic accuracy for clinically relevant conditions [increased liver stiffness measurement (LSM), at-risk metabolic dysfunction–associated steatohepatitis, advanced fibrosis, or cirrhosis) was assessed. Subgroup analysis included stratification by age group and diabetes/obesity status. We analysed 11,404 participants. Metabolic dysfunction–associated fibrosis 5 (MAF-5) obtained the highest AUC for increased LSM (≥8 kPa: 0.80; ≥12 kPa: 0.87) and advanced fibrosis (AUC: 0.90). Fibrotic NASH index and MAF-5 performed best for detecting metabolic dysfunction–associated steatohepatitis (AUC: 0.93 and AUC: 0.92, p =ns) and SAFE for cirrhosis (AUC: 0.92). To obtain 80% sensitivity for LSM ≥8 kPa, the corresponding MAF-5 cut-off resulted in fewer referrals (42%) compared to fibrosis-4 index (77%) and higher specificity (62% vs. 24%); MAF-5 was also superior for detection of LSM ≥12 kPa and advanced fibrosis. Age-dependent scores yielded lower sensitivity among younger individuals, for example, by referring 20% of the population with the highest NIT scores, the fibrosis-4 index, steatosis-associated fibrosis estimator, NAFLD fibrosis score, FORNS, and Hepamet fibrosis score yielded <10% sensitivity for LSM ≥8 kPa among individuals aged 18–35 years, while fibrotic NASH index and MAF-5 obtained 40% and 71%. Conclusions: Of the 10 investigated NITs, MAF-5 discriminated best between all conditions except cirrhosis, for which the steatosis-associated fibrosis estimator yielded the highest accuracy. The performance of the fibrosis-4 index was poor, implying that referral pathways for significant liver disease in low-prevalence populations can be improved when more accurate NITs such as MAF-5 are employed.
- 7 May 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 591-602
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction
Background and Aims: Screening for liver disease in the general population requires accurate non-invasive tests (NITs). A head-to-head comparison of NITs for early detection of clinically relevant liver disease among the target population for screening is lacking. Aproach and Results: Among the meta-cohort (Rotterdam Study and National Health and Nutrition Examination Survey) with metabolic dysfunction aged 18–80 years, 10 NITs were investigated. The diagnostic accuracy for clinically relevant conditions [increased liver stiffness measurement (LSM), at-risk metabolic dysfunction–associated steatohepatitis, advanced fibrosis, or cirrhosis) was assessed. Subgroup analysis included stratification by age group and diabetes/obesity status. We analysed 11,404 participants. Metabolic dysfunction–associated fibrosis 5 (MAF-5) obtained the highest AUC for increased LSM (≥8 kPa: 0.80; ≥12 kPa: 0.87) and advanced fibrosis (AUC: 0.90). Fibrotic NASH index and MAF-5 performed best for detecting metabolic dysfunction–associated steatohepatitis (AUC: 0.93 and AUC: 0.92, p =ns) and SAFE for cirrhosis (AUC: 0.92). To obtain 80% sensitivity for LSM ≥8 kPa, the corresponding MAF-5 cut-off resulted in fewer referrals (42%) compared to fibrosis-4 index (77%) and higher specificity (62% vs. 24%); MAF-5 was also superior for detection of LSM ≥12 kPa and advanced fibrosis. Age-dependent scores yielded lower sensitivity among younger individuals, for example, by referring 20% of the population with the highest NIT scores, the fibrosis-4 index, steatosis-associated fibrosis estimator, NAFLD fibrosis score, FORNS, and Hepamet fibrosis score yielded <10% sensitivity for LSM ≥8 kPa among individuals aged 18–35 years, while fibrotic NASH index and MAF-5 obtained 40% and 71%. Conclusions: Of the 10 investigated NITs, MAF-5 discriminated best between all conditions except cirrhosis, for which the steatosis-associated fibrosis estimator yielded the highest accuracy. The performance of the fibrosis-4 index was poor, implying that referral pathways for significant liver disease in low-prevalence populations can be improved when more accurate NITs such as MAF-5 are employed.
- Open Access
- 14 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis
Background: Steatotic liver disease (SLD) affects ~30% of adults worldwide. The global population is continuously threatened by epidemic and endemic viral diseases. This study aims to thoroughly examine the interaction between SLD and major viral diseases. Methods: We systematically searched databases from inception to April 2, 2024, for observational studies recording viral-infected adult patients with eligible data on the presence of hepatic steatosis. Results: Six hundred thirty-six eligible studies were included in the analysis of SLD prevalence. Among patients with monoinfections, the highest SLD prevalence was observed in those infected with HCV at 49% (95% CI: 47%–51%), followed by SARS-CoV-2 (39%, 95% CI [34%–44%]), HIV (39%, 95% CI [33%–44%]), and HBV (36%, 95% CI [32%–40%]). Additionally, co-infections, such as HCV-HIV and HBV-HCV, exhibit even higher SLD prevalence. The prevalence of steatohepatitis is particularly high in HIV-infected (24%, 95% CI: 17%–30%) and HCV-infected (18%, 95% CI: 13%–24%) populations. The co-existence of SLD with viral infections was associated not only with the progression of liver disease but also with more severe outcomes of the infections and poorer responses to antiviral treatment. The combination of cardiometabolic risk factors and viral-associated and host factors contributes to the higher risk of SLD in viral-infected populations. Conclusions: SLD is highly prevalent in viral-infected populations, and the reciprocal interactions between SLD and viral diseases exacerbate both conditions, leading to poorer patient outcomes in general.
- 14 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Open AccessThe global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis
Background: Steatotic liver disease (SLD) affects ~30% of adults worldwide. The global population is continuously threatened by epidemic and endemic viral diseases. This study aims to thoroughly examine the interaction between SLD and major viral diseases. Methods: We systematically searched databases from inception to April 2, 2024, for observational studies recording viral-infected adult patients with eligible data on the presence of hepatic steatosis. Results: Six hundred thirty-six eligible studies were included in the analysis of SLD prevalence. Among patients with monoinfections, the highest SLD prevalence was observed in those infected with HCV at 49% (95% CI: 47%–51%), followed by SARS-CoV-2 (39%, 95% CI [34%–44%]), HIV (39%, 95% CI [33%–44%]), and HBV (36%, 95% CI [32%–40%]). Additionally, co-infections, such as HCV-HIV and HBV-HCV, exhibit even higher SLD prevalence. The prevalence of steatohepatitis is particularly high in HIV-infected (24%, 95% CI: 17%–30%) and HCV-infected (18%, 95% CI: 13%–24%) populations. The co-existence of SLD with viral infections was associated not only with the progression of liver disease but also with more severe outcomes of the infections and poorer responses to antiviral treatment. The combination of cardiometabolic risk factors and viral-associated and host factors contributes to the higher risk of SLD in viral-infected populations. Conclusions: SLD is highly prevalent in viral-infected populations, and the reciprocal interactions between SLD and viral diseases exacerbate both conditions, leading to poorer patient outcomes in general.
- 4 November 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (1) , 192-193
Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
- 4 November 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (1) , 192-193
Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
- Open Access
- 23 August 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (12) , 101193
Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD
- 23 August 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (12) , 101193
Open AccessDifferential prevalence and prognostic value of metabolic syndrome components among patients with MASLD
- Top Cited PapersOpen Access
- 19 March 2024
- Published by Elsevier in Gastroenterology
- Vol. 167 (2) , 357-367.e9
Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
- 19 March 2024
- Published by Elsevier in Gastroenterology
- Vol. 167 (2) , 357-367.e9
Top Cited PapersOpen AccessMetabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
- Open Access
- 2 December 2023
- Published by Elsevier in JHEP Reports
- Vol. 6 (2) , 100980
Association of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBV
- 2 December 2023
- Published by Elsevier in JHEP Reports
- Vol. 6 (2) , 100980
Open AccessAssociation of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBV
- Open Access
- 26 October 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (2) , 243-250
Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe
- 26 October 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (2) , 243-250
Open AccessHepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe